Top

Published in:

Open Access 01-12-2021 | Omalizumab | Case report

Long term treatment with omalizumab in adolescent with refractory solar urticaria

Authors: Mauro Iannelli, Stefano Passanisi, Giuseppe Crisafulli, Stefania Arasi, Lucia Caminiti, Giuseppina Zirilli, Giovanni B. Pajno

Published in: Italian Journal of Pediatrics | Issue 1/2021

Abstract

Background

Solar urticaria represents an uncomfortable form of chronic inducible urticaria. First and second-line treatments are ineffective in some patients, leading to an impairment in their quality of life. Omalizumab represents a safe therapeutic option in case of refractory solar urticaria.

Case presentation

We update a case of a 21-year-old Caucasian girl affected by solar urticaria from the age of 14. Poor disease control was achieved with standard or high-dose of H₁-antihistamines. Several omalizumab courses, including a 1-year-long course, were practiced resulting in clinical remission and significant improvement in patient’s quality of life.

Conclusion

Our experience confirms the effectiveness and safety of omalizumab for the management of refractory solar urticaria. Future studies are awaited in order to monitor long term effects and chronic doses of this treatment, particularly in patients who need concomitant therapy with antihistamines.

Goetze S, Elsner P. Solar Urticaria. J Dtsch Dermatol Ges. 2015;13(12):1250–3. https://doi.org/10.1111/ddg.12809.CrossRefPubMed

Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J All Clin Immunol. 2018;141(2):638–64. https://doi.org/10.1016/j.jaci.2017.06.032.CrossRef

Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. https://doi.org/10.1186/s13052-019-0695-x.CrossRefPubMedPubMedCentral

Crisafulli G, Caminiti L, Chiera F, Arasi S, Salzano G, Panasiti I, et al. Omalizumab in children with severe allergic disease: a case series. Ital J Pediatr. 2019;45(1):13. https://doi.org/10.1186/s13052-019-0602-5.CrossRefPubMedPubMedCentral

Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33(4):e13489. https://doi.org/10.1111/dth.13489.CrossRefPubMed

Damiani G, Diani M, Conic RRZ, Colli C, Ferrucci S, Martina E, et al. Omalizumab in chronic Urticaria: an Italian survey. Int Arch Allergy Immunol. 2019;178(1):45–9. https://doi.org/10.1159/000492532.CrossRefPubMed

Arasi S, Crisafulli G, Caminiti L, Guarneri F, Aversa T, Porcaro F, et al. Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol. 2015;26(6):583–5. https://doi.org/10.1111/pai.12413.CrossRefPubMed

Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, et al. Omalizumab for the treatment of solar urticaria: case series and systematic review of the literature. J Allergy Clin Immunol Pract. 2018;4(4):1198–204. https://doi.org/10.1016/j.jaip.2018.02.032.CrossRef

Silva PM, Costa AC, Mendes A, Barbosa MP. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015;43(2):168–73. https://doi.org/10.1016/j.aller.2013.11.007.CrossRef

10.

Saini SS, MacGlashan DW, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624–30.PubMed

11.

Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ J. 2014;7(1):17. https://doi.org/10.1186/1939-4551-7-17.CrossRefPubMedPubMedCentral

12.

Adachi M, Kozawa M, Yoshisue H, Milligan KL, Nagasaki M, Sasajima T, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan. Respir Med. 2018;141:56–63. https://doi.org/10.1016/j.rmed.2018.06.021.CrossRefPubMed

13.

Santamaría L, Sánchez J. Eficacia a largo plazo del omalizumab en pacientes con queratoconjuntivitis vernal resistente a tratamiento convencional [Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis]. Rev Alerg Mex. 2018;65(2):192–6. https://doi.org/10.29262/ram.v65i2.292.CrossRefPubMed

14.

Passanisi S, Caminiti L, Zirilli G, Lombardo F, Crisafulli G, Aversa T, et al. Biologics in food allergy: up-to-date. Expert Opin Biol Ther. 2021;21(9):1–9. https://doi.org/10.1080/14712598.2021.1904888.CrossRef

15.

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–414. https://doi.org/10.1111/all.13397.CrossRefPubMed

16.

Chang J, Cattelan L, Ben-Shoshan M, Le M, Netchiporouk E. Management of Pediatric Chronic Spontaneous Urticaria: a review of current evidence and guidelines. J Asthma Allergy. 2021;14:187–99. https://doi.org/10.2147/JAA.S249765.CrossRefPubMedPubMedCentral

17.

Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2010;125(2):490–1. https://doi.org/10.1016/j.jaci.2009.11.007.CrossRefPubMed

18.

Moncourier M, Assikar S, Matei I, Souyri N, Couture M, Rigot E, et al. Visible light-induced solar urticaria is improved by omalizumab. Photodermatol Photoimmunol Photomed. 2016;32(5-6):314–6. https://doi.org/10.1111/phpp.12271.CrossRefPubMed

19.

Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705–12. https://doi.org/10.1111/all.13345.CrossRefPubMed

20.

Straesser MD, Oliver E, Palacios T, Kyin T, Patrie J, Borish L. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6:1386–1388.e1.CrossRef

21.

Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: assessment of action spectra and impact on quality of life in adults and children. Photodermatol Photoimmunol Photomed. 2018;34(4):262–8. https://doi.org/10.1111/phpp.12385.CrossRefPubMed

22.

Can PK, Etikan P, Degirmentepe EN, Kocaturk E. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria. Asian Pac J Allergy Immunol. 2021. https://doi.org/10.12932/AP-180920-0965.

Title: Long term treatment with omalizumab in adolescent with refractory solar urticaria
Authors: Mauro Iannelli
Stefano Passanisi
Giuseppe Crisafulli
Stefania Arasi
Lucia Caminiti
Giuseppina Zirilli
Giovanni B. Pajno
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Omalizumab
Urticaria
Published in: Italian Journal of Pediatrics / Issue 1/2021
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-021-01151-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long term treatment with omalizumab in adolescent with refractory solar urticaria

Abstract

Background

Case presentation

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era

Incidence and predictors of mortality among neonates referred to comprehensive and specialized hospitals in Amhara regional state, North Ethiopia: a prospective follow-up study

Severe onset of inflammatory myositis in a child: think to paraneoplastic myositis

CMV, B and C hepatitis among multi-transfused hereditary hemolytic Anemia children: an updated Egyptian experience

Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease